Altimmune
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Its last 5 Sell calls were followed by a 20% average decline over the next quarter.
- Recent price momentum is -62.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 21.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 1.41
- Open
- 1.37
- Day range
- 1.32 - 1.46
- Avg price
- 1.36
- Volume
- 4.06M
- Turnover
- 5.52M
- Turnover ratei
- 2.33%
- Volume ratioi
- 0.88
- Amplitudei
- 9.93%
- 52-week rangei
- 1.32 - 6.44
Valuation
- P/Ei
- -1.33
- P/E (TTM)i
- -1.87
- P/Bi
- 0.58
- EPSi
- -1.00
- Book value / shi
- 2.28
- Net profit
- -194.59M
- Net assets
- 443.66M
Share structure
- Market cap
- 258.80M
- Float capi
- 231.84M
- Shares out
- 194.59M
- Float sharesi
- 174.31M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
79.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-4.86M net over the window
Short interest
- Shares short
- 42.13M
- % of floati
- 21.66%
- Days to coveri
- 12.16
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Altimmune (ALT)?
Altimmune last traded at 1.33. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Altimmune's market cap?
About 258.80M.
What is the P/E ratio of Altimmune?
The trailing twelve-month P/E is -1.87. The Valuation tab shows it against the stock's own five-year range.
Does Altimmune pay a dividend?
Altimmune does not currently pay a regular dividend.
Is Altimmune a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 18.50, which implies 1291.0% upside from the current price. This is not investment advice.
What is Altimmune's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Altimmune a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.
Altimmune discussion 0 comments